Skip to content
Axcess News – Lifestyle
Author:
InflaRx N.V.
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 28, 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
April 9, 2026
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
March 13, 2026
←
Previous Page
1
2